Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVC-COV1901 vs AZD1222 Immunogenicity Study
NCT05426343Phase 3Completed
- Sponsor
- Medigen Biotechnology
- Start
- Jul 2022
- Primary completion
- Oct 2022
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of MVC-COV1901 in coronavirus disease 2019 (COVID-19), sponsored by Medigen Biotechnology. Started Jul 2022; status: completed.
02
Drugs
MVC-COV1901
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05426343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05426343.